Extended Mutational Profiling for Metastatic Colorectal Cancer (CRC): beyond RAS Molecular Spectrum of KRAS-NRAS-BRAF and PI3K in Cancer Colorectal

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Otero
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors S. Otero1, P. Saldias2, M. Sanchez2, M. Colica1, G. Bramuglia3, G. Jankilevich1
  • 1Oncology Unit. Hospital Dr. Carlos G. Durand, Ciudad Autonoma de Buenos Aires, Argentina, /
  • 2Hospital Carlos G Durand, Buenos Aires, Argentina, /
  • 3Fundación Investigar, Buenos Aires, Argentina, /


Long term survival was achieved in metastatic colorectal cancer. One of the cornerstones was the close the gap between the clinic and molecular biology laboratory. Data from multiple phase III trials have indicated that KRAS mutations can be considered a highly specific negative biomarker of response to anti-EGFR monoclonal antibodies. The specifıc genetic background of the tumor largely influences the effıcacy of anti-EGFR therapies. Nearly 70% of CRC samples have heterogeneous genetic alterations in genes involved in EGFR signaling, which negatively affect response to the monoclonal antibodies.


We investigated the prevalence of mutations in the KRAS, BRAF, NRAS and PI3K in colorectal carcinoma patients from Buenos Aires-Argentina. Here, we present the frequency of oncogenés mutations.